• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

MyRisk_Stroke Calculator: A Personalized Stroke Risk Assessment Tool for the General Population.
CONCLUSIONS: The MyRisk_Stroke Calculator is a simple method of disseminating information to the general population about their stroke risk. PMID: 24465256 [PubMed]
Source: Journal of Clinical Neurology - December 2, 2014 Category: Neurology Tags: J Clin Neurol Source Type: research

Increased risk of ischaemic stroke among patients with multiple sclerosis
ConclusionsMultiple sclerosis is declared to be associated with an increased risk in developing stroke, which requires closer attention to this group of patients for stroke prevention, especially in the younger population.
Source: European Journal of Neurology - November 29, 2014 Category: Neurology Authors: C.‐H. Tseng, W.‐S. Huang, C.‐L. Lin, Y.‐J. Chang Tags: Original Article Source Type: research

Secondary prevention of stroke in elderly people in Poland--results of PolSenior study.
CONCLUSIONS: Secondary cardiovascular preventive therapy in Poland is used too rarely in older people after stroke, and it especially concerns anticoagulant therapy in those with a history of atrial fibrillation. Structured educational programmes should be developed in Poland to improve usage of secondary preventive therapy in the elderly. PMID: 24821632 [PubMed - indexed for MEDLINE]
Source: Neurologia i Neurochirurgia Polska - August 24, 2014 Category: Neurology Authors: Labuz-Roszak B, Skrzypek M, Pierzchała K, Machowska-Majchrzak A, Mossakowska M, Chudek J, Mańka-Gaca I, Bartman W, Więcek A Tags: Neurol Neurochir Pol Source Type: research

Increased risk of stroke in patients with chronic kidney disease after recurrent hypoglycemia
Conclusions: CKD was associated with a higher risk of stroke and mortality in patients with hypoglycemia. Recurrent hypoglycemia considerably increased the risk of stroke and overall mortality in patients with CKD regardless of whether they had diabetes. These results suggest that hypoglycemia has a crucial role in stroke and death in patients with CKD.
Source: Neurology - August 18, 2014 Category: Neurology Authors: Yu, T.-M., Lin, C.-L., Chang, S.-N., Sung, F.-C., Kao, C.-H. Tags: Prognosis, All Cerebrovascular disease/Stroke, Cohort studies ARTICLE Source Type: research

Modification of Outcomes With Aspirin or Apixaban in Relation to Female and Male Sex in Patients With Atrial Fibrillation: A Secondary Analysis of the AVERROES Study Brief Reports
Conclusions— Female patients with atrial fibrillation had higher ischemic stroke rates compared with male patients, but the relative effects of apixaban compared with aspirin on both ischemic stroke and bleeding were similar in men and women.
Source: Stroke - June 23, 2014 Category: Neurology Authors: Lip, G. Y. H., Eikelboom, J., Yusuf, S., Shestakovska, O., Hart, R. G., Connolly, S., on behalf of the AVERROES Investigators Tags: Other anticoagulants, Thrombosis risk factors Brief Reports Source Type: research

Stroke in Patients With Aortic Stenosis: The Simvastatin and Ezetimibe in Aortic Stenosis Study Clinical Sciences
Conclusions— In patients with aortic stenosis not prescribed oral anticoagulation, atrial fibrillation, AVR with concomitant coronary artery bypass grafting, and CHA2DS2-VASc score were the major predictors of stroke. Incident stroke was strongly associated with mortality. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT00092677.
Source: Stroke - June 23, 2014 Category: Neurology Authors: Greve, A. M., Dalsgaard, M., Bang, C. N., Egstrup, K., Ray, S., Boman, K., Rossebo, A. B., Gohlke-Baerwolf, C., Devereux, R. B., Kober, L., Wachtell, K. Tags: Thrombosis risk factors, CV surgery: valvular disease, Acute Cerebral Infarction Clinical Sciences Source Type: research

Rivaroxaban for Stroke Prevention in East Asian Patients From the ROCKET AF Trial Clinical Sciences
Conclusions— Observed relative efficacy and safety of rivaroxaban versus warfarin were similar among patients within and outside East Asia. Rivaroxaban, 20 mg once daily, is an alternative to warfarin for stroke prevention in East Asians with nonvalvular atrial fibrillation. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT00123456.
Source: Stroke - May 27, 2014 Category: Neurology Authors: Wong, K. S. L., Hu, D. Y., Oomman, A., Tan, R.-S., Patel, M. R., Singer, D. E., Breithardt, G., Mahaffey, K. W., Becker, R. C., Califf, R., Fox, K. A. A., Berkowitz, S. D., Hacke, W., Hankey, G. J., on behalf of The Executive Steering Committee and the RO Tags: Other anticoagulants, Embolic stroke, Anticoagulants Clinical Sciences Source Type: research

Determinants of high sensitivity cardiac troponin T elevation in acute ischemic stroke
Conclusions: Established CHD and cardiovascular risk factors are associated with hs-cTnT elevation. Acute MI is likely underdiagnosed in acute ischemic stroke patients. Dynamic changes in troponin levels seem to be related to poor short-term prognosis.
Source: BMC Neurology - May 3, 2014 Category: Neurology Authors: Kashif FaizBente ThommessenGunnar EinvikPål BrekkeTorbjørn OmlandOle Rønning Source Type: research

Intracranial Hemorrhage Among Patients With Atrial Fibrillation Anticoagulated With Warfarin or Rivaroxaban: The Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation Clinical Sciences
Conclusions— Among patients with atrial fibrillation treated with anticoagulation, the risk of ICH was higher among Asians, blacks, the elderly, and in those with previous stroke or transient ischemic attack, increased diastolic blood pressure, and reduced platelet count or serum albumin at baseline. The risk of ICH was significantly lower in patients with heart failure and in those who were randomized to rivaroxaban instead of warfarin. The external validity of these findings requires testing in other atrial fibrillation populations.
Source: Stroke - April 28, 2014 Category: Neurology Authors: Hankey, G. J., Stevens, S. R., Piccini, J. P., Lokhnygina, Y., Mahaffey, K. W., Halperin, J. L., Patel, M. R., Breithardt, G., Singer, D. E., Becker, R. C., Berkowitz, S. D., Paolini, J. F., Nessel, C. C., Hacke, W., Fox, K. A. A., Califf, R. M., on behal Tags: Acute Cerebral Hemorrhage, Anticoagulants Clinical Sciences Source Type: research

Dabigatran etexilate for secondary stroke prevention: the first year experience from a multicenter short-term registry
Discussion: Our pilot data indicate that dabigatran appears to be safe for secondary stroke prevention during the first year of implementation of this therapy. However, high cost may limit the long-term treatment of AF patients with dabigatran, leading to early discontinuation.
Source: Therapeutic Advances in Neurological Disorders - April 22, 2014 Category: Neurology Authors: Tsivgoulis, G., Krogias, C., Sands, K. A., Sharma, V. K., Katsanos, A. H., Vadikolias, K., Papageorgiou, S. G., Heliopoulos, I., Shiue, H., Mitsoglou, A., Liantinioti, C., Athanasiadis, D., Giannopoulos, S., Piperidou, C., Voumvourakis, K., Alexandrov, A. Tags: Original Research Source Type: research

Robert E. Lee's Last Stand: His Dying Words and the Stroke That Killed Him. (P1.294)
CONCLUSIONS: Lee suffered chronic angina and congestive heart failure, with a probable myocardial infarction during the war. His death stemmed from an acute, possibly cardioembolic stroke manifesting as expressive aphasia, and subsequent respiratory complications. Given his aphasia, Lee’s famous last words are questionable.Disclosure: Dr. Southerland has received personal compensation in an editorial capacity for Neurology Podcast.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Southerland, A. Tags: History of Neurology Source Type: research

Updated Meta-analysis of Hemodilution in Acute Ischemic Stroke (P1.113)
CONCLUSION: Future work includes an additional reviewer to assess trial quality and CENTRAL search up to 2013. Overall, the results of this meta-analysis were comparable to the 2002 meta-analysis with a trend suggesting the possibility of harm with hemodilution therapy.Study Supported by:NIH NCATS UL1TR000427 and NHLBI Fellowship F30HL112491.Disclosure: Dr. Chang has nothing to disclose. Dr. Jensen has nothing to disclose.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Chang, T., Jensen, M. Tags: Cerebrovascular Disease and Interventional Neurology: Antiplatelet Agents and Miscellaneous Source Type: research

Cryptogenic Stroke with More Than One Cause versus No Cause by TOAST Classification Lacks Adequate Predictive Power for Stroke Risk Factors and Outcomes (P1.116)
Conclusion: Differentiating between cryptogenic more than one cause and cryptogenic no cause demonstrates significant difference in the rates of cardiac-related, vasculature-related, and outcome variables. However, cryptogenic more than one cause does not have significant predictive power in demographic, baseline, or outcome prediction models.Disclosure: Dr. Scullen has nothing to disclose. Dr. Monlezun, Jr has nothing to disclose. Dr. George has received research support from Tulane University School of Medicine. Dr. Siegler has nothing to disclose. Dr. Schwickrath has nothing to disclose. Dr. El Khoury has nothing to dis...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Scullen, T., Monlezun, D., George, A., Siegler, J., Schwickrath, M., El Khoury, R., Martin-Schild, S. Tags: Cerebrovascular Disease and Interventional Neurology: Ischemic Stroke Subtype Source Type: research

"No Turn Back Approach" to Reduce Treatment Time for Endovascular Treatment of Acute Ischemic Stroke (P4.214)
Conclusions: The "no turn back approach" appeared to be feasible and reduced the time interval between ED arrival and microcatheter placement in acute ischemic stroke patients undergoing endovascular treatment.Disclosure: Dr. Egila has nothing to disclose. Dr. Malik has nothing to disclose. Dr. Siddiqi has nothing to disclose. Dr. Mian has nothing to disclose. Dr. Hassan has nothing to disclose. Dr. Miley has nothing to disclose. Dr. Rodriguez has nothing to disclose. Dr. Suri has nothing to disclose. Dr. Qureshi has nothing to disclose.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Egila, H., Adil, M., Siddiqi, H., Mian, N., Hassan, A., Miley, J., Rodriguez, G., Suri, M., Qureshi, A. Tags: Cerebrovascular Disease and Interventional Neurology: Acute Stroke Endovascular Source Type: research

Thrombolytic Treatment for Acute Ischemic Stroke Patients with History of Migraine Headaches (P4.223)
Conclusion: Patients with migraine headaches receiving IV rt-PA treatment for acute ischemic stroke appear to have a lower rates of death and disability most likely related to their decreased rates of intracerebral hemorrhage.Disclosure: Dr. Malik has nothing to disclose. Dr. Malik has nothing to disclose. Dr. Nickles has nothing to disclose. Dr. Qureshi has nothing to disclose.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Malik, A., Adil, M., Chaudhry, S., Qureshi, A. Tags: Cerebrovascular Disease and Interventional Neurology: Acute Stroke Thrombolysis Source Type: research

Pages: 1  2  3  4  5  6  7  8  9  10  11  12  13  14